Certara, Inc. (NASDAQ:CERT) Receives $8.85 Average Price Target from Analysts

Shares of Certara, Inc. (NASDAQ:CERT) have received an average rating of “Hold” from the thirteen analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $8.85.

A number of analysts have recently issued reports on CERT shares. Morgan Stanley lowered their price objective on Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Wall Street Zen cut Certara from a “buy” rating to a “hold” rating in a research report on Sunday, February 15th. Robert W. Baird lowered their price objective on Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 12th. Leerink Partners restated an “outperform” rating and set a $10.00 price objective on shares of Certara in a research report on Thursday, February 26th. Finally, TD Cowen restated a “buy” rating on shares of Certara in a research report on Thursday, February 26th.

Certara Stock Performance

CERT opened at $5.35 on Friday. The firm has a market capitalization of $832.30 million, a P/E ratio of -53.50 and a beta of 1.53. The stock’s 50 day moving average price is $5.72 and its two-hundred day moving average price is $7.42. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.28. Certara has a 12-month low of $4.45 and a 12-month high of $13.88.

Certara (NASDAQ:CERT) last released its earnings results on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The business had revenue of $106.92 million during the quarter, compared to analyst estimates of $106.13 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The business’s quarterly revenue was up .8% compared to the same quarter last year. During the same period last year, the business earned $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, equities analysts forecast that Certara will post 0.29 earnings per share for the current year.

Institutional Trading of Certara

A number of institutional investors and hedge funds have recently modified their holdings of CERT. AQR Capital Management LLC bought a new stake in shares of Certara during the first quarter valued at approximately $259,000. Goldman Sachs Group Inc. boosted its stake in Certara by 65.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock valued at $2,267,000 after buying an additional 90,724 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Certara by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock valued at $2,965,000 after buying an additional 35,954 shares in the last quarter. Jane Street Group LLC boosted its stake in Certara by 17.1% in the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock valued at $2,743,000 after buying an additional 40,463 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Certara by 29.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock valued at $1,089,000 after buying an additional 21,099 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.